Vakaramoko "karam" Diaby

Vakaramoko "karam" Diaby, Ph.D., M.Sc.

Assistant Professor

Department: Pharmaceutical Outcomes & Policy
Business Phone: (352) 273-9397
Business Email: v.diaby@cop.ufl.edu

About Vakaramoko "karam" Diaby

Dr. Diaby is currently the Track Director, Applied PharmacoEconomics for the UF Online Masters and an Assistant Professor of Pharmaceutical Outcomes and Policy, College of Pharmacy. He is also affiliated with the Cancer Population Science group – UF Cancer Center. As the Track Director of the Applied Pharmacoeconomics Track, he manages a team of instructors and is the Track content expert and its development and growth. He also represents the Track at conferences and events. As an Assistant Professor, he is responsible for teaching applied pharmacoeconomics in the Pharm D, residential and online program in Pharmaceutical Outcomes and Policy. Dr. Diaby has published over 50 peer-reviewed publications, including two book chapters. Dr. Diaby was the PI on a pilot project grant from the NIH/NIMHD, a Mitacs grant (Canada), and currently serves as a co-investigator on an NIH/NHGRI grant. He is the PI on a Nicklaus Children’s Hospital foundation pharmacogenomics grant and a Co-PI on an industry (Merck) contract. Dr. Diaby serves as a health economist on an HIV Telemedicine grant sponsored by the CDC. He completed a sub-award from a U54 center grant (U54OH011230) to study the impact of heat-related illness on the gross domestic product, agricultural and health sectors of the Southeastern and Coastal Center for Agricultural Health and Safety (SCCAHS)’ catchment area. He has been contributing service to the College of Pharmacy by sitting on the curriculum and faculty governance committees. He is a grant peer-reviewer for three international agencies (UK, New Zealand, and The Netherlands) and a peer-reviewer for several academic journals. Dr. Diaby was an academic editor for the journal PLOS ONE and currently serves on the editorial board of Pharmacoeconomics-Open. He has prior consulting experience with Pharma (e.g. Pfizer, Amgen in Canada; Merck in the US) and the Ontario government (Canada) and serves as a subject matter expert on several projects.

Board Certifications

  • Clinical Research Associate
    Sup Sante Paris – France

Research Profile

Health economics; Pharmacoeconomics; Comparative effectiveness research; Health disparities; Multi-Criteria Decision Analysis (MCDA); Policy evaluations

Open Researcher and Contributor ID (ORCID)

0000-0002-6251-0773

Areas of Interest
  • Breast Cancers
  • Health disparities and vulnerable populations
  • Pharmacogenomics
  • Women’s Health

Publications

2021
A pharmacovigilance study to quantify the strength of association between the combination of antimalarial drugs and azithromycin and cardiac arrhythmias: implications for the treatment of COVID-19.
Expert review of pharmacoeconomics & outcomes research. 21(1):159-168 [DOI] 10.1080/14737167.2021.1851600. [PMID] 33186061.
2021
Effects, trends, costs associated with readmission in early-aged patients with suicidal ideation.
Expert review of pharmacoeconomics & outcomes research. [DOI] 10.1080/14737167.2021.1914593. [PMID] 33827359.
2021
Evaluation of statin discontinuation stratified by primary versus secondary prevention following bariatric surgery: a retrospective cohort study.
Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery. [DOI] 10.1016/j.soard.2021.01.025. [PMID] 33648887.
2020
A cost-effectiveness analysis of trastuzumab-containing treatment sequences for HER-2 positive metastatic breast cancer patients in Taiwan.
Breast (Edinburgh, Scotland). 49:141-148 [DOI] 10.1016/j.breast.2019.11.012. [PMID] 31805500.
2020
A quantitative analysis of the effect of continuity of care on 30-day readmission and in-hospital mortality among patients with acute ischemic stroke.
Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association. 29(9) [DOI] 10.1016/j.jstrokecerebrovasdis.2020.105053. [PMID] 32807459.
2020
Cost-Effectiveness Analysis of Adjuvant Neratinib Following Trastuzumab in Early-Stage HER2-Positive Breast Cancer.
Journal of managed care & specialty pharmacy. 26(2) [DOI] 10.18553/jmcp.2020.26.2.221. [PMID] 32011959.
2020
Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data.
The pharmacogenomics journal. 20(5):724-735 [DOI] 10.1038/s41397-020-0162-5. [PMID] 32042096.
2020
Cost-Effectiveness of Subsequent Whole-Brain Radiotherapy or Hippocampal-Avoidant Whole-Brain Radiotherapy Versus Stereotactic Radiosurgery or Surgery Alone for Treatment of Melanoma Brain Metastases.
Applied health economics and health policy. 18(5):679-687 [DOI] 10.1007/s40258-020-00560-1. [PMID] 32157631.
2020
Cost-effectiveness of treatments for HER2-positive metastatic breast cancer and associated metastases: an overview of systematic reviews.
Expert review of pharmacoeconomics & outcomes research. 1-12 [DOI] 10.1080/14737167.2021.1848553.
2020
Dataset used in the economic evaluation trastuzumab-based regimens for HER-2 positive metastatic breast cancer patients in the Taiwanese healthcare setting.
Data in Brief. 29 [DOI] 10.1016/j.dib.2020.105194. [PMID] 32071975.
2020
Examining factors associated with adherence to hormonal therapy in breast cancer patients.
Research in social & administrative pharmacy : RSAP. 16(4):574-582 [DOI] 10.1016/j.sapharm.2019.08.005. [PMID] 31473108.
2020
Identification of risk factors of 30-day readmission and 180-day in-hospital mortality, and its corresponding relative importance in patients with Ischemic heart disease: a machine learning approach.
Expert review of pharmacoeconomics & outcomes research. 1-6 [DOI] 10.1080/14737167.2021.1842200. [PMID] 33131344.
2020
In our war against the opioid epidemic, could ‘weed’ be a winner?
Expert review of pharmacoeconomics & outcomes research. 20(5):423-429 [DOI] 10.1080/14737167.2020.1807944.
2020
Predicting Cost-Effectiveness of Generic vs. Brand Dabigatran Using Pharmacometric Estimates Among Patients with Atrial Fibrillation in the United States.
Clinical and translational science. 13(2):352-361 [DOI] 10.1111/cts.12719. [PMID] 32053288.
2020
Prevalence and effects of suicidal ideation diagnosis code position in claims on readmission rate estimates.
Research in social & administrative pharmacy : RSAP. [DOI] 10.1016/j.sapharm.2020.09.003. [PMID] 32928656.
2020
Real-World Clinical and Economic Outcomes Associated with Palbociclib for HR-Positive/HER-2 Negative Metastatic Breast Cancer: A commentary
Journal Of Managed Care & Specialty Pharmacy.
2020
Real-World Clinical and Economic Outcomes Associated with Palbociclib for HR-Positive/HER2 Negative Metastatic Breast Cancer: A Commentary.
Journal of managed care & specialty pharmacy. 26(7):826-831 [DOI] 10.18553/jmcp.2020.26.7.826. [PMID] 32584682.
2020
Self-assessed life expectancy among older adults in Côte d’Ivoire.
BMC public health. 20(1) [DOI] 10.1186/s12889-020-09034-4. [PMID] 32539697.
2020
Timing, Costs, and Survival Outcome of Specialty Palliative Care in Medicare Beneficiaries With Metastatic Non-Small-Cell Lung Cancer.
JCO oncology practice. 16(12):e1532-e1542 [DOI] 10.1200/OP.20.00298. [PMID] 33006914.
2020
Timing, Costs, and Survival Outcome of Specialty Palliative Care in Medicare Beneficiaries With Metastatic Non–Small-Cell Lung Cancer
JCO Oncology Practice. 16(12):e1532-e1542 [DOI] 10.1200/op.20.00298.
2020
Using time series analysis to forecast the health-related quality of life of post-menopausal women with non-metastatic ER+ breast cancer: A tutorial and case study.
Research in social & administrative pharmacy : RSAP. 16(8):1095-1099 [DOI] 10.1016/j.sapharm.2019.11.009. [PMID] 31753693.
2019
Comparative effectiveness of radiotherapy for early-stage hormone receptor-positive breast cancer in elderly women using real-world data.
Cancer medicine. 8(1):117-127 [DOI] 10.1002/cam4.1904. [PMID] 30548840.
2019
Multicriteria Decision Analysis to Support Health Technology Assessment Agencies: Benefits, Limitations, and the Way Forward.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 22(11):1283-1288 [DOI] 10.1016/j.jval.2019.06.014. [PMID] 31708065.
2019
Value Assessment Frameworks in the United States: A Call for Patient Engagement.
PharmacoEconomics – open. 3(1):1-3 [DOI] 10.1007/s41669-018-0094-z. [PMID] 30182346.
2018
An Evaluation of the Clinical Therapeutic Effect of Lixisenatide in Type 2 Diabetes Patients: A Systematic Literature Review.
Current diabetes reviews. 14(4):363-375 [DOI] 10.2174/1573399813666170724113240. [PMID] 28738763.
2018
An Evaluation of the Cost-effectiveness of Comprehensive MTM Integrated with Point-of-Care Phenotypic and Genetic Testing for U.S. Elderly Patients After Percutaneous Coronary Intervention.
Journal of managed care & specialty pharmacy. 24(2):142-152 [DOI] 10.18553/jmcp.2018.24.2.142. [PMID] 29384027.
2018
Longitudinal Effects of Adjuvant Endocrine Therapy on the Quality of Life of Post-menopausal Women with Non-metastatic ER+ Breast Cancer: A Systematic Review.
PharmacoEconomics – open. 2(4):359-369 [DOI] 10.1007/s41669-018-0070-7. [PMID] 29470807.
2017
Comparison of health utility weights among elderly patients receiving breast-conserving surgery plus hormonal therapy with or without radiotherapy.
Current medical research and opinion. 33(2):391-400 [DOI] 10.1080/03007995.2016.1257983. [PMID] 27819160.
2017
Economic evaluation of sequencing strategies in HER2-positive metastatic breast cancer in Mexico: a contrast between public and private payer perspectives.
Breast cancer research and treatment. 166(3):951-963 [DOI] 10.1007/s10549-017-4473-4.
2016
Cost-effectiveness analysis of 1st through 3rd line sequential targeted therapy in HER2-positive metastatic breast cancer in the United States.
Breast cancer research and treatment. 160(1):187-196 [PMID] 27654970.
View on: PubMed
2016
ELICIT: An alternative imprecise weight elicitation technique for use in multi-criteria decision analysis for healthcare.
Expert review of pharmacoeconomics & outcomes research. 16(1):141-7 [DOI] 10.1586/14737167.2015.1083863. [PMID] 26361235.
2016
Parameterization of a disease progression simulation model for sequentially treated metastatic human epidermal growth factor receptor 2 positive breast cancer patients.
Current medical research and opinion. 32(6):991-6 [DOI] 10.1185/03007995.2016.1149056. [PMID] 26824145.
2016
Preventing Unnecessary Costs of Drug-Induced Hypoglycemia in Older Adults with Type 2 Diabetes in the United States and Canada.
PloS one. 11(9) [DOI] 10.1371/journal.pone.0162951. [PMID] 27648831.
2015
A review of systematic reviews of the cost-effectiveness of hormone therapy, chemotherapy, and targeted therapy for breast cancer.
Breast cancer research and treatment. 151(1):27-40 [DOI] 10.1007/s10549-015-3383-6. [PMID] 25893588.
2015
Application of multicriteria decision analysis in health care: a systematic review and bibliometric analysis.
Health expectations : an international journal of public participation in health care and health policy. 18(6):1894-905 [DOI] 10.1111/hex.12287. [PMID] 25327341.
2015
Improving Health Care Decision Making in the USA Through Comparative Effectiveness Research: The Role of Economic Evaluation
Pharmaceutical Medicine. 29(5):247-253 [DOI] 10.1007/s40290-015-0113-7.
2015
Multi-criteria decision analysis for health technology assessment in Canada: insights from an expert panel discussion.
Expert review of pharmacoeconomics & outcomes research. 15(1):13-9 [DOI] 10.1586/14737167.2015.965155. [PMID] 25267699.
2015
Multicriteria decision analysis in oncology.
Health expectations : an international journal of public participation in health care and health policy. 18(6):1812-26 [DOI] 10.1111/hex.12178. [PMID] 24635949.
2015
Sedative-hypnotic medicines and falls in community-dwelling older adults: a cost-effectiveness (decision-tree) analysis from a US Medicare perspective.
Drugs & aging. 32(4):305-14 [DOI] 10.1007/s40266-015-0251-3. [PMID] 25825121.
2014
Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer.
Breast cancer research and treatment. 147(2):433-41 [DOI] 10.1007/s10549-014-3042-3. [PMID] 25012857.
2014
How to use multi-criteria decision analysis methods for reimbursement decision-making in healthcare: a step-by-step guide.
Expert review of pharmacoeconomics & outcomes research. 14(1):81-99 [DOI] 10.1586/14737167.2014.859525. [PMID] 24328890.
2014
Re: Xie J, Diener M, De G, et al. Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in the United States. J Med Econ 2014;16(2):278-88.
Journal of medical economics. 17(4):248-9 [DOI] 10.3111/13696998.2014.892883. [PMID] 24506762.
2014
Survival modeling for the estimation of transition probabilities in model-based economic evaluations in the absence of individual patient data: a tutorial.
PharmacoEconomics. 32(2):101-8 [DOI] 10.1007/s40273-013-0123-9. [PMID] 24338265.
2014
Using quality-adjusted progression-free survival as an outcome measure to assess the benefits of cancer drugs in randomized-controlled trials: case of the BOLERO-2 trial.
Breast cancer research and treatment. 146(3):669-73 [DOI] 10.1007/s10549-014-3047-y. [PMID] 25017612.
2013
Exploring the state of pharmacy profession: The perspective of Côte d’Ivoire
Currents in Pharmacy Teaching and Learning. 5(5):470-476 [DOI] 10.1016/j.cptl.2013.06.005.
2013
Introduction to health economics and decision-making: Is economics relevant for the frontline clinician?
Best practice & research. Clinical gastroenterology. 27(6):831-44 [DOI] 10.1016/j.bpg.2013.08.016. [PMID] 24182604.
2013
Multi-criteria decision analysis (MCDA) in health care: a bibliometric analysis
Operational Research. 2(1):20-24 [DOI] 10.1016/j.orhc.2013.03.001.
2013
Which criteria are considered in healthcare decisions? Insights from an international survey of policy and clinical decision makers.
International journal of technology assessment in health care. 29(4):456-65 [DOI] 10.1017/S0266462313000573. [PMID] 24290340.
2011
A Proposed Framework for Formulary Listing in Low-Income Countries
Pharmaceutical Medicine. 25:71-82 [DOI] 10.1007/BF03256848.
2011
An application of a proposed framework for formulary listing in low-income countries: the case of Côte d’Ivoire.
Applied health economics and health policy. 9(6):389-402 [DOI] 10.2165/11595220-000000000-00000. [PMID] 22017499.
2011
Eliciting preferences for reimbursed drugs selection criteria in Côte d’Ivoire.
The patient. 4(2):125-31 [DOI] 10.2165/11586060-000000000-00000. [PMID] 21766901.
2007
Economic impact of Tibolone compared with Continuous-Combined Hormone Replacement Therapy in the management of climacteric symptoms in postmenopausal women.
Maturitas. 58(2):138-49 [PMID] 17870259.
View on: PubMed
A Study on Self-Assessed Life Expectancy Among Older Adults in Côte d’Ivoire
. [DOI] 10.21203/rs.3.rs-15595/v1.
Self-Assessed Life Expectancy Among Older Adults In Côte D’ivoire
. [DOI] 10.21203/rs.3.rs-15595/v3.
Self-Assessed Life Expectancy Among Older Adults in Côte D’Ivoire
. [DOI] 10.21203/rs.3.rs-15595/v2.

Grants

Mar 2021 ACTIVE
Incorporating Health Equity into Value Assessment: Frameworks, Promising Alternatives, and Future Directions
Role: Principal Investigator
Funding: PHRMA FOU
Jan 2021 ACTIVE
CDK 4/6 inhibitors use among metastatic breast cancer patients: Early discontinuation and management of adverse events
Role: Principal Investigator
Funding: PFIZER INC
May 2020 ACTIVE
Epidemiology and cost of RSV infections in infants and toddlers
Role: Co-Investigator
Funding: MERCK AND COMPANY INC
Jan 2020 – Dec 2020
ECONOMIC EVALUATION OF RAPID WHOLE GENOME SEQUENCING (rWGS) IN CRITICALLY ILL CHILDREN AND ADOLESCENTS: THE CASE OF THE NICKLAUS CHILDRENS HOSPITAL
Role: Principal Investigator
Funding: NICKLAUS CHILDRENS HOSPITAL
Sep 2016 ACTIVE
Southeastern and Coastal Center for Agricultural Health and Safety (SCC-AHS)
Role: Project Manager
Funding: CTRS FOR DIS CNTRL INST OCCUP SFTY HLTH

Education

Ph.D.
2011 · University of Montreal
M.Sc.
2006 · University of Montreal

Teaching Profile

Courses Taught
2018,2020-2021
PHA6910 Supervised Research
2019-2021
PHA7980 Research for Doctoral Dissertation
2017-2021
PHA7979 Advanced Research
2018-2021
PHA6286 Pharmaceutical Microeconomics
2020
PHA6806 Pharmacoeconomic Modeling
2019-2020
PHA6935 Selected Topics in Pharmacy
2018-2020
PHA6287 Pharmaceutical Health Economics
2018-2021
PHA5876C Pt Care 8 Complex Pts
2018,2020-2021
PHA6971 Research for Master’s Thesis
2018-2021
PHA6265 Introduction to Pharmaceutical Outcomes and Policy I
2018-2019,2021
PHA5787C Pt Care 5: Endo
2018-2019,2021
PHA5784C Pt Care 4: GI and Renal
2021
PHA6936 Advanced Topics in Pharmaceutical Sciences
2021
PHA6937 Topics in Pharmaceutical Administration
2021
PHA6940 Supervised Teaching
2021
PHA5787 Pharmacotherapy 5

Contact Details

Phones:
Business:
(352) 273-9397
Emails:

Recent news

Dr. Karam Diaby participates in National Human Genome Research Institute Strategic Planning Workshop

The strategic planning workshop will help NHGRI establish a “2020 vision for genomics” and culminate in the publication of a new NHGRI strategic plan.

POP faculty publish findings on cancer and quality of life

The study, partially funded by a UF College of Pharmacy PROSPER award, was published in Pharmacoeconomics Open.

Dr. Diaby’s MTM study published in the Journal of Managed Care and Specialty Pharmacy

Diaby’s team used a decision analytic model to simulate and compare the cost and effectiveness associated with treatment strategies.

Dr. Karam Diaby invited to participate in Health Research Council of New Zealand’s review of research proposals

Diaby will assist in a peer-review of research applications to improve pharmaceutical outcomes.